NasdaqGS:RXRXBiotechs
Recursion’s AI Drug Programs Show Early Clinical Progress And Valuation Gap
Recursion Pharmaceuticals (NasdaqGS:RXRX) reported positive early clinical milestones across several AI-driven drug programs.
REC-1245 showed encouraging early safety data in humans.
Patient dosing has started for REC-4539, moving another asset into active clinical testing.
REC-4881 produced meaningful efficacy signals in familial adenomatous polyposis, prompting engagement with the FDA about a potential registrational path.
For investors watching NasdaqGS:RXRX, these program updates focus...